HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bo Gronlund Selected Research

Platinum Compounds (Compounds, Platinum)

10/2004Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?
8/2004Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?
10/2002Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Bo Gronlund Research Topics

Disease

4Ovarian Epithelial Carcinoma
04/2005 - 04/2002
3Carcinoma (Carcinomatosis)
04/2005 - 08/2004
2Neoplasms (Cancer)
10/2004 - 08/2004
2Neutropenia
10/2002 - 04/2002
1Ovarian Neoplasms (Ovarian Cancer)
08/2004
1Thrombocytopenia (Thrombopenia)
04/2002
1Hypersensitivity (Allergy)
04/2002

Drug/Important Bio-Agent (IBA)

5Topotecan (Hycamtin)FDA LinkGeneric
04/2005 - 04/2002
4PlatinumIBA
04/2005 - 04/2002
4Paclitaxel (Taxol)FDA LinkGeneric
10/2004 - 04/2002
3Platinum Compounds (Compounds, Platinum)IBA
10/2004 - 10/2002
3Carboplatin (JM8)FDA LinkGeneric
10/2004 - 04/2002
1taxaneIBA
04/2005
1Etoposide (VP 16)FDA LinkGeneric
04/2005
1CA-125 Antigen (CA 125 Antigen)IBA
10/2004
1Indicators and Reagents (Reagents)IBA
08/2004
1Cytostatic AgentsIBA
04/2002

Therapy/Procedure

3Drug Therapy (Chemotherapy)
04/2005 - 08/2004